US Attorney scrutinizes Copaxone marketing

Share this article:

The US Attorney's Office for the Southern District of New York is looking into how Teva marketed its MS drug Copaxone and Parkinson's medication Azilect since 2006. The Associated Press reports that the drugmaker announced the investigation Monday and is exploring “possible violations of the False Claims Act.” Citi research analyst Liav Abraham told the AP that the FDA has increased its False Claims investigations over the past few years and that they can take several years to wrap.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.